First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Szarvas, Nóra, Szilágyi, Ágnes, Tasic, Velibor, Nushi-Stavileci, Valbona, Sofijanova, Aspazija, Gucev, Zoran, Szabó, Miklós, Szabó, Attila, Szeifert, Lilla, Reusz, György, Rusai, Krisztina, Arbeiter, Klaus, Müller, Thomas, Prohászka, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295478/
https://www.ncbi.nlm.nih.gov/pubmed/25496981
http://dx.doi.org/10.1186/s13052-014-0101-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295478/
https://www.ncbi.nlm.nih.gov/pubmed/25496981
http://dx.doi.org/10.1186/s13052-014-0101-7

Ejemplares similares